The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

@article{Tan2016TheIA,
  title={The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.},
  author={Daniel S.W. Tan and Sue S Yom and Ming Sound Tsao and Harvey I. Pass and Karen Kelly and Nir Peled and Rex Chin-Wei Yung and Ignacio Wistuba and Yasushi Yatabe and Michael Unger and Philip C. Mack and Murry W. Wynes and Tetsuya Mitsudomi and Walter Weder and David F. Yankelevitz and Roy S. Herbst and David R. Gandara and David Paul Carbone and Paul A. Bunn and Tony Shu Kam Mok and Fred R Hirsch},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2016},
  volume={11 7},
  pages={946-63}
}
Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…